Publikationen 2022

99. First-​line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-​R-ENDA Trial. Braulke F, Zettl F, Ziepert M, Viardot A, Kahl C, Prange-​Krex G, Korfel A, Dreyling M, Bott A, Wedding U, Reichert D, de Wit M, Hartmann F, Poeschel V, Schmitz N, Witzens-​Harig M, Klapper W, Rosenwald A, Wulf G, Altmann B, Trümper L. Hemasphere. 2022 Dec 1;6(12):e808. doi: 10.1097/HS9.0000000000000808. eCollection 2022 Dec. PMID: 36479544

98. Pooled analysis of first-​line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older. Simon F, Giza A, Robrecht S, Fink AM, Cramer P, von Tresckow J, Fürstenau M, Goede V, Tausch E, Schneider C, Stilgenbauer S, Wendtner CM, Eichhorst B, Fischer K, Hallek M, Al-​Sawaf O. Leuk Lymphoma. 2022 Dec;63(14):3299-3306.

97. Exploration of whole genome and transcriptome sequencing data lacks evidence for oncogenic viral elements to drive the pathogenesis of T-cell prolymphocytic leukemia. Patil P, Toprak UH, Seufert J, Braun T, Bernhart SH, Wiehle L, Müller A, Schlesner M, Herling M, Lichter P, Stilgenbauer S, Siebert R, Zapatka M. Leuk Lymphoma. 2022 Dec;63(13):3253-3256. Epub 2022 Sep 9.

96. First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience. Kreutmair S, Pfeifer D, Waterhouse M, Takács F, Graessel L, Döhner K, Duyster J, Illert AL, Frey AV, Schmitt M, Lübbert M. Cancer Immunol Immunother. 2022 Dec;71(12):2913-2928. Epub 2022 Apr 27.

95. Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia. Beelen DW, Arnold R, Stelljes M, Alakel N, Brecht A, Bug G, Bunjes D, Faul C, Finke J, Franke GN, Holler E, Kobbe G, Kröger N, Rösler W, Scheid C, Schönland S, Stadler M, Tischer J, Wagner-Drouet E, Wendelin K, Brüggemann M, Reiser L, Hoelzer D, Gökbuget N. Transplant Cell Ther. 2022 Dec;28(12):834-842. Epub 2022 Aug 27.

94. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Knisbacher BA, Lin Z, Hahn CK, Nadeu F, Duran-Ferrer M, Stevenson KE, Tausch E, Delgado J, Barbera-Mourelle A, Taylor-Weiner A, Bousquets-Muñoz P, Diaz-Navarro A, Dunford A, Anand S, Kretzmer H, Gutierrez-Abril J, López-Tamargo S, Fernandes SM, Sun C, Sivina M, Rassenti LZ, Schneider C, Li S, Parida L, Meissner A, Aguet F, Burger JA, Wiestner A, Kipps TJ, Brown JR, Hallek M, Stewart C, Neuberg DS, Martín-Subero JI, Puente XS, Stilgenbauer S, Wu CJ, Campo E, Getz G. Nat Genet. 2022 Nov;54(11):1664-1674. Epub 2022 Aug 4.

93. Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS). Bielack SS, Blattmann C, Borkhardt A, Csóka M, Hassenpflug W, Kabíčková E, Kager L, Kessler T, Kratz C, Kühne T, Kevric M, Lehrnbecher T, Mayer-Steinacker R, Mettmann V, Metzler M, Reichardt P, Rossig C, Sorg B, von Luettichau I, Windhager R, Hecker-Nolting S. Eur J Cancer. 2022 Nov;176:50-57. Epub 2022 Sep 30.

92. Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia. Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L, Vannucchi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Berliner N, Borowitz MJ, Branford S, Brown AL, Cargo CA, Döhner H, Falini B, Garcia-Manero G, Haferlach T, Hellström-Lindberg E, Kim AS, Klco JM, Komrokji RS, Loh ML, Loghavi S, Mullighan CG, Ogawa S, Tefferi A, Papaemmanuil E, Reiter A, Ross DM, Savona MR, Shimamura A, Skoda RC, Sole F, Stone RM, Orazi A, Walter MJ, Wu D, Ebert BL, Cazzola M. Blood. 2022 Nov 24;140(21):2228-2247.

91. Response to "The WHO classification of haematolymphoid tumours" (Editorial). Swerdlow SH, Campo E, Arber DA, Cazzola M, Cook JR, Döhner H, Dreyling M, Hasserjian RP, Jaffe ES, Orazi A, Quintanilla-Martinez L, Scott DW, Tefferi A, Winter JN, Zelenetz AD. Leukemia. 2022 Nov;36(11):2748-2749. Epub 2022 Aug 27.

90. CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis. Schilhabel A, Walter PJ, Cramer P, von Tresckow J, Kohlscheen S, Szczepanowski M, Laqua A, Fischer K, Eichhorst B, Böttcher S, Schneider C, Tausch E, Brüggemann M, Kneba M, Hallek M, Ritgen M. Cancers (Basel). 2022 Oct 7;14(19):4917.

89. Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape. Mangolini M, Maiques-Diaz A, Charalampopoulou S, Gerhard-Hartmann E, Bloehdorn J, Moore A, Giachetti G, Lu J, Roamio Franklin VN, Chilamakuri CSR, Moutsopoulos I, Rosenwald A, Stilgenbauer S, Zenz T, Mohorianu I, D'Santos C, Deaglio S, Hodson DJ, Martin-Subero JI, Ringshausen I. Nat Commun. 2022 Oct 20;13(1):6220.

88. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia. Herbst SA, Vesterlund M, Helmboldt AJ, Jafari R, Siavelis I, Stahl M, Schitter EC, Liebers N, Brinkmann BJ, Czernilofsky F, Roider T, Bruch PM, Iskar M, Kittai A, Huang Y, Lu J, Richter S, Mermelekas G, Umer HM, Knoll M, Kolb C, Lenze A, Cao X, Österholm C, Wahnschaffe L, Herling C, Scheinost S, Ganzinger M, Mansouri L, Kriegsmann K, Kriegsmann M, Anders S, Zapatka M, Del Poeta G, Zucchetto A, Bomben R, Gattei V, Dreger P, Woyach J, Herling M, Müller-Tidow C, Rosenquist R, Stilgenbauer S, Zenz T, Huber W, Tausch E, Lehtiö J, Dietrich S. Nat Commun. 2022 Oct 20;13(1):6226.

87. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.Döhner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, Dombret H, Porkka K, Sandhu I, Skikne BS, See WL, Ugidos M, Risueño A, Chan ET, Thakurta A, Beach CL, Lopes de Menezes D. Blood. 2022 Oct 13;140(15):1674-1685.

86. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. Cramer P, Fürstenau M, Robrecht S, Giza A, Zhang C, Fink AM, Fischer K, Langerbeins P, Al-Sawaf O, Tausch E,Schneider C, Schetelig J, Dreger P, Böttcher S, Kreuzer KA, Schilhabel A, Ritgen M, Brüggemann M, Kneba M, Stilgenbauer S, Eichhorst B, Hallek M. Lancet Haematol. 2022 Oct;9(10):e745-e755. Epub 2022 Aug 18.

85. [Tumor of the right atrium with disseminated pulmonal metastases]. Kloth C, Brunner H, Vogele D, Beck A, Schönsteiner S, Beer AJ, Beer M, Thaiss WM. Radiologie (Heidelb). 2022 Oct;62(10):870-874. Epub 2022 Sep 6.

84. Association of FLT3-ITD length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis. Polak TB, Van Rosmalen J, Dirven S, Herzig JK, Cloos J, Meshinchi S, Döhner K, Janssen JJWM, Cucchi DGJ. Haematologica. 2022 Oct 1;107(10):2506-2510.

83. Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper. Bailly S, Cartron G, Chaganti S, Córdoba R, Corradini P, Düll J, Ferrarini I, Osborne W, Rosenwald A, Sancho JM, Tilly H, Van Den Neste E, Viardot A, Visco C. Hematol Oncol. 2022 Oct;40(4):505-517. Epub 2022 Jun 7.

82. Circulating tumor DNA-based MRD assessment in patients with CLL treated with obinutuzumab, acalabrutinib and venetoclax. Fürstenau M, Weiss J, Giza A, Franzen F, Robrecht S, Fink AM, Fischer K, Schneider C, Tausch E, Stilgenbauer S, Ritgen M, Schilhabel A, Brüggemann M, Eichhorst B, Hallek M, Cramer P. Clin Cancer Res. 2022 Oct 3;28(19):4203-4211.

81. Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: an ALWP/EBMT analysis. Nagler A, Ngoya M, Galimard JE, Labopin M, Bornhäuser M, Stelljes M, Finke J, Ganser A, Einsele H, Kröger N, Brecht A, Bethge W, Edinger M, Kulagin A, Passweg J, Blau IW, Elmaagacli A, Schäfer-Eckart K, Platzbecker U, Schroeder T, Bunjes D, Tischer J, Martin S, Spyridonidis A, Giebel S, Savani B, Mohty M. Clin Cancer Res. 2022 Oct 3;28(19):4258-4266.

80. The Renovated Face of EHA Classical Master Class: A Survey-based Evaluation on Behalf of the EHA Campus Working Group. Gurnari C, Bouaziz M, Marinova J, van Havre N, Döhner K, Ar MC. Hemasphere. 2022 Sep 21;6(10):e777. No abstract available.

79. Broad genomic workup including optical genome mapping uncovers a DDX3X: MLLT10 gene fusion in acute myeloid leukemia. Nilius-Eliliwi V, Tembrink M, Gerding WM, Lubieniecki KP, Lubieniecka JM, Kankel S, Liehr T, Mika T, Dimopoulos F, Döhner K, Schroers R, Nguyen HHP, Vangala DB. Front Oncol. 2022 Sep 9;12:959243. doi: 10.3389/fonc.2022.959243. eCollection 2022. PMID: 36158701.

78. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.Jahn N, Jahn E, Saadati M, Bullinger L, Larson RA, Ottone T, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Ehninger G, Heuser M, Ganser A, Pallaud C, Gathmann I, Krzykalla J, Benner A, Bloomfield CD, Thiede C, Stone RM, Döhner H, Döhner K. Leukemia. 2022 Sep;36(9):2218-2227. Epub 2022 Aug 3.

77. Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele GJ, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B. Blood. 2022 Sep 22;140(12):1345-1377.

76. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL. Katz DA, Morris JD, Chu MP, David KA, Thieblemont C, Morley NJ, Khan SS, Viardot A, Martín García-Sancho A, Rodríguez-García G, Bastos-Oreiro M, Lee ST, Kormany W, Chen Y, Wong HL, Anderson AA, Katlinskaya Y, Avilion AA, Dai T, González-Barca E. Leuk Lymphoma. 2022 Sep;63(9):2063-2073. Epub 2022 May 3.

75. Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody.  Greiner J, Goetz M, Schuler PJ, Bulach C, Hofmann S, Schrezenmeier H, Dӧhner H, Schneider V, Guinn BA. Br J Haematol. 2022 Sep;198(5):866-874. Epub 2022 Jul 7.

74. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared to stage III/IV. Los-de Vries GT, Stevens WBC, van Dijk EV, Langois-Jacques C, Clear AJ, Stathi P, Roemer MGM, Mendeville M, Hijmering NJ, Sander B, Rosenwald A, Calaminici M, Hoster E, Hiddemann W, Gaulard P, Salles GA, Horn H, Klapper W, Xerri L, Burton C, Tooze RM, Smith AG, Buske C, Scott DW, Natkunam Y, Advani R, Sehn LH, Raemaekers JM, Gribben JG, Kimby EK, Kersten MJ, Maucort-Boulch D, Ylstra B, de Jong D. Blood Adv. 2022 Sep 27;6(18):5482-5493.

73. International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes J, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey E, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Goekbuget N, Gotlib JR, Hellström-Lindberg E, Hobbs G, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, Löwenberg B, Macintyre EA, Malcovati L, Mullighan CG, Niemeyer CM, Odenike O, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer C, Schmitt-Graeff A, Shimamura A, Sierra J, Stock W, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Döhner H, Tefferi A.Blood. 2022 Sep 15;140(11):1200-1228.

72. The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice. Meri S, Bunjes D, Cofiell R, Jodele S. Adv Ther. 2022 Sep;39(9):3896-3915. Epub 2022 Jul 4. Review.

71. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.  Döhner H, Weber D, Krzykalla J, Fiedler W, Wulf GG, Salih HR, Lübbert M, Kühn M, Schroeder T, Salwender H, Götze KS, Westermann J, Fransecky L, Mayer K, Hertenstein B, Ringhoffer M, Tischler HJ, Machherndl-Spandl S, Schrade A, Paschka P, Gaidzik VI, Theis F, Thol FR, Heuser M, Schlenk RF, Bullinger L, Saadati M, Benner A, Larson RA, Stone RM, Döhner K, Ganser A. Blood Adv. 2022 Sep 27;6(18):5345-5355.

70. Modeling the B-cell receptor signaling on single cell level reveals a stable network circuit topology between non-malignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors. Wolf C, Maus C, Persicke MR, Filarsky K, Tausch E, Schneider C, Döhner H, Stilgenbauer S, Lichter P, Höfer T, Mertens D. Int J Cancer. 2022 Sep 1;151(5):783-796.

69. Experienced stigma and applied coping strategies during the COVID-19 pandemic in Germany: a mixed-methods study.Peters L, Burkert S, Brenner C, Grüner B. BMJ Open. 2022 Aug 24;12(8):e059472.

68. Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia. Zhai Y, Singh P, Dolnik A, Brazda P, Atlasy N, Del Gaudio N, Döhner K, Döhner H, Minucci S, Martens J, Altucci L, Megchelenbrink W, Bullinger L, Stunnenberg HG. Mol Cancer. 2022 Aug 19;21(1):166.

67. Unified classification and risk-stratification in Acute Myeloid Leukemia. Tazi Y, Arango-Ossa JE, Zhou Y, Bernard E, Thomas I, Gilkes A, Freeman S, Pradat Y, Johnson SJ, Hills R, Dillon R, Levine MF, Leongamornlert D, Butler A, Ganser A, Bullinger L, Döhner K, Ottmann O, Adams R, Döhner H, Campbell PJ, Burnett AK, Dennis M, Russell NH, Devlin SM, Huntly BJP, Papaemmanuil E. Nat Commun. 2022 Aug 8;13(1):4622.

66. How a Medical Association Can Make a Difference in a Crisis Situation. van Havre N, Orsini E, Almeida A, Gribben J, Bolanos N, Doeswijk R, Gaidano G, Mouhssine S, Döhner K, Grønbæk K, Porkka K, Macintyre E. Hemasphere. 2022 Aug 9;6(9):e765. eCollection 2022 Sep. No abstract available.

65. Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma.Buske C. Lancet Oncol. 2022 Aug;23(8):967-969. Epub 2022 Jul 5.

64. Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. Davies A, Kater AP, Sharman JP, Stilgenbauer S, Vitolo U, Klein C, Parreira J, Salles G. Future Oncol. 2022 Aug;18(26):2943-2966. Epub 2022 Jul 20. Review.

63. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. von Tresckow J, Cramer P, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Fürstenau M, Illmer T, Klaproth H, Tausch E, Ritgen M, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst BF, Hallek M. Leukemia. 2022 Aug;36(8):2125-2128. Epub 2022 Jun 25.

62. The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements.Grasedieck S, Cabantog A, MacPhee L, Im J, Ruess C, Demir B, Sperb N, Rücker FG, Döhner K, Herold T, Pollack JR, Bullinger L, Rouhi A, Kuchenbauer F. Haematologica. 2022 Aug 1;107(8):1758-1772.

61. A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial. Hess G, Hüttmann A, Witzens-Harig M, Dreyling MH, Keller U, Marks R, Ernst T, Pott C, Viardot A, Frontzek F, Trautmann M, Ruckes C, Deuster O, Rosenwald A, Theobald M, Lenz G. Br J Haematol. 2022 Aug;198(3):482-491.

60. T-cell prolymphocytic leukemia is associated with deregulation of oncogenic microRNAs on transcriptional and epigenetic level. Patil P, Hillebrecht S, Chteinberg E, López C, Toprak UH, Seufert J, Bernhart SH, Kretzmer H, Bergmann AK, Bens S, Högel J, Scheffold A, Chelliah Jebaraj BM, Schrader A, Johansson P, Costa D, Schlesner M, Dürig J, Herling M, Campo E, Stilgenbauer S, Wiehle L, Siebert R. Genes Chromosomes Cancer. 2022 Jul;61(7):432-436.

59. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Rosée P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, Gørløv JS, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Zanni M, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Thurner L, Cabras G, Pennese E, Ponzoni M, Deckert M, Politi LS, Finke J, Ferranti A, Cozens K, Burger E, Ielmini N, Cavalli F, Zucca E, Illerhaus G; IELSG32 study investigators. Leukemia. 2022 Jul;36(7):1870-1878.

58. The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia. Rusyn L, Reinartz S, Nikiforov A, Mikhael N, Vom Stein A, Kohlhas V, Bloehdorn J, Stilgenbauer S, Lohneis P, Buettner R, Robrecht S, Fischer K, Pallasch C, Hallek M, Nguyen PH, Seeger-Nukpezah T. Leukemia. 2022 Jul;36(7):1794-1805.

57. Defining disease modification in myelofibrosis in the era of targeted therapy. Pemmaraju N, Verstovsek S, Mesa R, Gupta V, Garcia JS, Scandura JM, Oh ST, Passamonti F, Döhner K, Mead AJ. Cancer. 2022 Jul 1;128(13):2420-2432. Review.

56. Prospective comparison of outcomes with azacitidine and decitabine in AML patients ineligible for intensive chemotherapy. Zeidan AM, Fenaux P, Gobbi M, Mayer J, Roboz GJ, Krauter J, Robak T, Kantarjian HM, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva LT, Demeter J, Griffiths EA, Yee KW, Issa JJ, Bewersdorf JPP, Keer HN, Hao Y, Azab M, Döhner H. Blood 2022 Jul 21;140(3):285-289. No abstract available.

55. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Stathis A, Mey U, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle DL, Hess D, Moccia AA, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W. Blood Adv. 2022 Jul 12;6(13):3911-3920.

54. Ivosidenib and Azacitidine in IDH1-Mutated AML. Reply. Montesinos P, de Botton S, Döhner H. N Engl J Med. 2022;386(26):2536-2537.

53. Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than MAPK/ERK pathway mutations.  Tausch E, Ljungström V, Agathangelidis A, Zapatka M, Scarfò L, Jebaraj BMC, Yosifov DY, Müller A, Munugalavadla V, Degenhardt JD, Ghia P, Rosenquist R, Stilgenbauer S. Blood. 2022 Jun 2;139(22):3340-3344. No abstract available.

52. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M, Stilgenbauer S as Collaborator; SHINE Investigators. N Engl J Med. 2022 Jun 30;386(26):2482-2494.

51. UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment. Bastian L, Hartmann AM, Beder T, Hänzelmann S, Kässens J, Bultmann M, Hoeppner MP, Franzenburg S, Wittig M, Franke A, Nagel I, Spielmann M, Reimer N, Busch H, Schwartz S, Steffen B, Viardot A, Döhner K, Kondakci M, Wulf G, Wendelin K, Renzelmann A, Kiani A, Trautmann H, Neumann M, Gökbuget N, Brüggemann M, Baldus CD. Leukemia. 2022 Jun;36(6):1676-1680. No abstract available.

50. Initial Risk Assessment in Patients with Alveolar Echinococcosis-Results from a Retrospective Cohort Study.Peters L, Burkert S, Hagemann JB, Albes R, Klemptner J, Birkle J, Schwaibold E, Siefermann S, Grüner B. Pathogens. 2022 May 9;11(5):557.

49. Targetable alterations in primary extranodal diffuse large B-cell lymphoma. Weissinger SE, Dugge R, Disch M, Barth TF, Bloehdorn J, Zahn M, Marienfeld R, Viardot A, Möller P. EJHaem. 2022 May 23;3(3):688-697. eCollection 2022 Aug.

48. A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia. Panayiotidis P, Tumyan G, Thieblemont C, Ptushkin VV, Marin-Niebla A, García-Sanz R, Le Gouill S, Stathis A, Bottos A, Hamidi H, Katz P, Perretti T, Willis JC, Buske C. Leuk Lymphoma. 2022 May;63(5):1058-1069.

47. Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies. Platzbecker U, Chromik J, Krönke J, Handa H, Strickland S, Miyazaki Y, Wermke M, Sakamoto W, Tachibana Y, Taube T, Germing U. BMC Cancer. 2022 May 21;22(1):569.

46. The EHA Research Roadmap: Malignant Lymphoid Diseases. Dreyling M, André M, Gökbuget N, Tilly H, Jerkeman M, Gribben J, Ferreri A, Morel P, Stilgenbauer S, Fox C, Maria Ribera J, Zweegman S, Aurer I, Bödör C, Burkhardt B, Buske C, Dollores Caballero M, Campo E, Chapuy B, Davies A, de Leval L, Doorduijn J, Federico M, Gaulard P, Gay F, Ghia P, Grønbæk K, Goldschmidt H, Kersten MJ, Kiesewetter B, Landman-Parker J, Le Gouill S, Lenz G, Leppä S, Lopez-Guillermo A, Macintyre E, Mantega MVM, Moreau P, Moreno C, Nadel B, Okosun J, Owen R, Pospisilova S, Pott C, Robak T, Spina M, Stamatopoulos K, Stary J, Tarte K, Tedeschi A, Thieblemont C, Trappe RU, Trümper LH, Salles G. Hemasphere. 2022 May 19;6(6):e726. eCollection 2022 Jun. No abstract available.

45. Couples Coping With Hematological Cancer: Support Within and Outside the Couple - Findings From a Qualitative Analysis of Dyadic Interviews. Bodschwinna D, Weissflog G, Döhner H, Niederwieser D, Mehnert-Theuerkauf A, Gündel H, Ernst J, Goerling U, Hönig K. Front Psychol. 2022 May 19;13:855638. eCollection 2022.

44. Classification of myeloid neoplasms/acute leukemia: global perspectives and the International Consensus Classification (ICC) approach. Arber DA, Hasserjian RP, Orazi A, Mathews V, Roberts AW, Schiffer CA, Roug AS, Cazzola M, Döhner H, Tefferi A.Am J Hematol. 2022 May;97(5):514-518.

43. Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. Kutsch N, Pallasch C, Decker T, Hebart H, Chow KU, Graeven U, Kisro J, Kroeber A, Tausch E, Fischer K, Fink AM, Wendtner CM, Ritgen M, Stilgenbauer S, Zhang D, Li B, Jürgensmeier JM, Rajakumaraswamy N, Bhargava P, Hallek M, Eichhorst B. Hemasphere. 2022 May 25;6(6):e729. eCollection 2022 Jun. No abstract available.

42. Severe immune thrombocytopenia following diphtheria, tetanus, pertussis and polio vaccination in a 36-year-old Caucasian woman: a case report. Küster O, Schmohl J, Greiner J, Storz MA. Eur J Med Res. 2022 May 3;27(1):63.

41. Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods. Kotrova M, Koopmann J, Trautmann H, Alakel N, Beck J, Nachtkamp K, Steffen B, Raffel S, Viardot A, Wethmar K, Darzentas N, Baldus CD, Goekbuget N, Brüggemann M. Blood Adv. 2022 May 24;6(10):3006-3010.

40. IgG seroprevalence of COVID-19 among people living with HIV or at high risk of HIV in south-west Germany: A seroprevalence study. Kaddu-Mulindwa D, Keuser L, Lesan V, Rissland J, Smola S, Werdecker V, Stilgenbauer S, Christofyllakis K, Thurner L, Bewarder M, Lohr B, Lutz J, Lohse S, Rieke A. HIV Med. 2022 May;23(5):564-569.

39. Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6. Clay-Gilmour A, Chattopadhyay S, Hildebrandt MAT, Thomsen H, Weinhold N, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Schmidt B, Langer C, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Späth F, Houlston R, Goldschmidt H, Manasanch EE, Norman A, Kumar S, Rajkumar SV, Slager S, Försti A, Vachon CM, Hemminki K. Blood Cancer J. 2022 Apr 13;12(4):60. No abstract available.

38. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, Daigle SR, Hui J, Pandya SS, Gianolio DA, de Botton S, Döhner H. N Engl J Med. 2022 Apr 21;386(16):1519-1531.

37. Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma. Lisson CS, Lisson CG, Mezger MF, Wolf D, Schmidt SA, Thaiss WM, Tausch E, Beer AJ, Stilgenbauer S, Beer M, Goetz M. Cancers (Basel). 2022 Apr 15;14(8):2008.

36. Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature.Grunenberg A, Sala E, Kapp-Schwoerer S, Viardot A. Expert Opin Pharmacother. 2022 Apr;23(5):561-571. Review.

35. TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event. Reckzeh K, Estruch M, Ali M, Søgaard Helbo A, Mosbech A, Jae Won K, Rücker F, Döhner K, Theilgaard-Mönch K. Br J Haematol. 2022 Apr;197(2):201-206. No abstract available.

34. 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years. Rieger K, De Filippi R, Lindén O, Viardot A, Hess G, Lerch K, Neumeister P, Stroux A, Peuker CA, Pezzutto A, Pinto A, Keller U, Scholz CW. Ann Hematol. 2022 Apr;101(4):781-788.

33. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. Garcia-Manero G, Döhner H, Wei AH, La Torre I, Skikne B, Beach CL, Santini V. Clin Lymphoma Myeloma Leuk. 2022 Apr;22(4):236-250. Review.

32. Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status. Roboz GJ, Ravandi F, Wei AH, Dombret H, Thol F, Voso MT, Schuh AC, Porkka K, La Torre I, Skikne BS, Zhong J, Beach CL, Risueño A, Lopes de Menezes D, Ossenkoppele GJ, Döhner H. Blood. 2022 Apr 7;139(14):2145-2155.

31. 18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting. Eberhardt N, Peters L, Kapp-Schwoerer S, Beer M, Beer AJ,  Grüner B, Thaiss WM. Pathogens. 2022 Mar 12;11(3):348.

30. Salvage Therapy for Alveolar Echinococcosis-A Case Series.Burkert S, Peters L, Bloehdorn J, Grüner B. Pathogens. 2022 Mar 9;11(3):333.

29. Increasing Role of Targeted Immunotherapies in the Treatment of AML.Greiner J, Götz M, Wais V. Int J Mol Sci. 2022 Mar 18;23(6):3304. Review.

28. Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. Kutsch N, Pallasch C, Tausch E, Böhme V, Ritgen M, Liersch R, Wacker A, Jacobs G, Trappe RU, Dreger P, Fischer K, Fink AM, Stilgenbauer S, Zhai S, Li B, Jürgensmeier JM, Rajakumaraswamy N, Bhargava P, Hallek M, Eichhorst BF. Hemasphere. 2022 Mar 8;6(4):e692. eCollection 2022 Apr. No abstract available.

27. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Huber H, Edenhofer S, von Tresckow J, Robrecht S, Zhang C, Tausch E, Schneider C, Bloehdorn J, Fürstenau M, Dreger P, Ritgen M, Illmer T, Illert AL, Durig J, Böttcher S, Niemann CU, Kneba M, Fink AM, Fischer K, Döhner H, Hallek M, Eichhorst B, Stilgenbauer S. Blood. 2022 Mar 3;139(9):1318-1329.

26. Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine. Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, Döhner H. J Clin Oncol. 2022 Mar 10;40(8):855-865.

25. Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. Bethge WA, Eyrich M, Mielke S, Meisel R, Niederwieser D, Schlegel PG, Schulz A, Greil J, Bunjes D, Brecht A, Kuball J, Schumm M, Vucinic V, Wiesneth M, Bonig H, Westinga K, Biedermann S, Holtkamp S, Karitzky S, Malchow M, Siewert C, Handgretinger R, Lang P. Bone Marrow Transplant. 2022 Mar;57(3):423-430.

24. Challenges of Hematopoietic Stem Cell Transplantation in the Era of COVID-19. Esagian SM, Giannis D, Ziogas IA, Gianni P, Sala E, Döhner H. Exp Clin Transplant. 2022 Mar;20(3):237-245.

23. Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients.Bloehdorn J, Krzykalla J, Holzmann K, Gerhardinger A, Jebaraj BMC, Bahlo J, Humphrey K, Tausch E, Robrecht S, Mertens D, Schneider C, Fischer K, Hallek M, Döhner H, Benner A, Stilgenbauer S. Haematologica. 2022 Mar 1;107(3):615-624.

22. Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune)therapy. Zapatka M, Tausch E, Öztürk S, Yosifov DY, Seiffert M, Zenz T, Schneider C, Blöhdorn J, Döhner H, Mertens D, Lichter P, Stilgenbauer S. Haematologica. 2022 Mar 1;107(3):604-614.

21. Echinococcus multilocularis specific antibody, systemic cytokine, and chemokine levels, as well as antigen-specific cellular responses in patients with progressive, stable, and cured alveolar echinococcosis: A 10-year follow-up.Grüner B, Peters L, Hillenbrand A, Voßberg P, Schweiker J, Rollmann EG, Rodriguez LH, Blumhardt J, Burkert S, Kern P, Köhler C, Soboslay PT. PLoS Negl Trop Dis. 2022 Feb 2;16(2):e0010099.

20. Evaluation of Serological Markers in Alveolar Echinococcosis Emphasizing the Correlation of PET-CTI Tracer Uptake with RecEm18 and Echinococcus-Specific IgG.Hotz JF,Peters L, Kapp-Schwörer S, Theis F, Eberhardt N, Essig A, Grüner B, Hagemann JB. Pathogens. 2022 Feb 12;11(2):239.

19. Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial. Kaddu-Mulindwa D, Lesan V, Berdel C, Stilgenbauer S, Bewarder M, Thurner L, Witzens-Harig M, Viardot A, Soekler M, Keller U, Truemper L, Christofyllakis K, Fleser O, Bittenbring JT, Poeschel V, Held G, Jagoda P. Leuk Lymphoma. 2022 Feb;63(2):326-334.

18. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Nat Med. 2022 Feb;28(2):325-332.

17. Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. Schmoll HJ, Lindner LH, Reichardt P, Heißner K, Kopp HG, Kessler T, Mayer-Steinacker R, Rüssel J, Egerer G, Crysandt M, Kasper B, Niederwieser D, Kunitz A, Eigendorff E, Petersen I, Steighardt J, Cygon F, Meinert F, Stein A. JAMA Oncol. 2021 Feb 1;7(2):255-262.

16. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Ng YLD, Ramberger E, Bohl SR, Dolnik A, Steinebach C, Conrad T, Müller S, Popp O, Kull M, Haji M, Gütschow M, Döhner H, Walther W, Keller U, Bullinger L, Mertins P, Krönke J. Nat Commun. 2022 Feb 23;13(1):1009.

15. Identification of recurrent genomic alterations in the apoptotic machinery in CLL patients treated with venetoclax monotherapy. Popovic R, Dunbar F, Lu C, Robinson K, Quarless D, Warder SE, Mukherjee N, Pesko J, Souers AJ, Waring JF, Davids MS, Tausch E, Stilgenbauer S, Ross JA, Leverson JD, Kim SY, Chyla BJ. Am J Hematol. 2022 Feb 1;97(2):E47-E51. No abstract available.

14. KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Kaddu-Mulindwa D, Altmann B, Robrecht S, Ziepert M, Regitz E, Tausch E, Held G, Poeschel V, Lesan V, Bittenbring JT, Thurner L, Pfreundschuh M, Christofyllakis K, Truemper L, Loeffler M, Schmitz N, Hoth M, Hallek M, Fischer K, Stilgenbauer S, Bewarder M, Rixecker TM. Lancet Haematol. 2022 Feb;9(2):e133-e142.

13. Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. Kwak LW, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Menne T, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Ogura M, Kim WS, Lee SJ, Kim SH, Ahn KY, Buske C. Clin Lymphoma Myeloma Leuk. 2022 Feb;22(2):89-97.

12. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Schnoeder TM, Schwarzer A, Jayavelu AK, Hsu CJ, Kirkpatrick J, Döhner K, Perner F, Eifert T, Huber N, Arreba-Tutusaus P, Dolnik A, Assi SA, Nafria M, Jiang L, Dai YT, Chen Z, Chen SJ, Kellaway SG, Ptasinska A, Ng ES, Stanley EG, Elefanty AG, Buschbeck M, Bierhoff H, Brodt S, Matziolis G, Fischer KD, Hochhaus A, Chen CW, Heidenreich O, Mann M, Lane SW, Bullinger L, Ori A, Eyss BV, Bonifer C, Heidel F. Blood. 2022 Feb 17;139(7):1080-1097.

11. Evaluation of vecabrutinib as a model for non-covalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.Jebaraj BMC, Müller A, Dheenadayalan RP, Endres S, Roessner PM, Seyfried F, Walliser C, Wist M, Qi J, Tausch E,Mertens D, Fox JA, Debatin KM, Meyer LH, Taverna P, Seiffert M, Gierschik P, Stilgenbauer S. Blood. 2022 Feb 10;139(6):859-875.

10. Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i). Gillessen S, Hüttmann A, Vucinic V, Müller H, Plütschow A, Viardot A, Topp MS, Kobe C, Böll B, Eichenauer DA, Sasse S, Haverkamp H, Schmitz C, Borchmann S, Bröckelmann PJ, Heger JM, Fuchs M, Engert A, Borchmann P, von Tresckow B. Br J Haematol. 2022 Feb;196(3):606-616.

9. TET3 promotes AML growth and epigenetically regulates glucose metabolism and leukemic stem cell associated pathways.Pulikkottil AJ, Bamezai S, Ammer T, Mohr F, Feder K, Vegi NM, Mandal T, Kohlhofer U, Quintanilla-Martinez L, Sinha A, Buske C, Rawat VPS. Leukemia. 2022 Feb;36(2):416-425.

8. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients. Öztürk S, Paul Y, Afzal S, Gil-Farina I, Jauch A, Bruch PM, Kalter V, Hanna B, Arseni L, Roessner PM, Schmidt M, Stilgenbauer S, Dietrich S, Lichter P, Zapatka M, Seiffert M. Leukemia. 2022 Feb;36(2):464-475.

7. Longitudinal CT Imaging to Explore the Predictive Power of 3D Radiomic Tumour Heterogeneity in Precise Imaging of Mantle Cell Lymphoma (MCL). Lisson CS, Lisson CG, Achilles S, Mezger MF, Wolf D, Schmidt SA, Thaiss WM, Bloehdorn J, Beer AJ, Stilgenbauer S, Beer M, Götz M. Cancers (Basel). 2022 Jan 13;14(2):393.

6. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Estey E, Hasserjian RP, Döhner H.Blood. 2022 Jan 20;139(3):323-332.

5. Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study. Schetelig J, Hoek J, Stilgenbauer S, Middeke JM, Andersen NS, Fox CP, Lenhoff S, Volin L, Shimoni A, Schroyens W, van Gelder M, Bunjes D, van Biezen A, Baldauf H, de Wreede LC, Tournilhac O, Kröger N, Yakoub-Agha I, Dreger P. Bone Marrow Transplant. 2022 Jan;57(1):144.

4. The CLL12 trial: Ibrutinib versus placebo in treatment-naïve, early stage chronic lymphocytic leukemia. Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M. Blood. 2022 Jan 13;139(2):177-187.

3. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Rücker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, Voso MT, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Savoie L, Sierra J, Pallaud C, Sanz MA, Jansen JH, Niederwieser D, Fischer T, Ehninger G, Heuser M, Ganser A, Bullinger L, Larson RA, Bloomfield CD, Stone RM, Döhner H, Thiede C, Döhner K.Leukemia. 2022 Jan;36(1):90-99.

2. Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review). Christofyllakis K, Bittenbring JT, Thurner L, Ahlgrimm M, Stilgenbauer S, Bewarder M, Kaddu-Mulindwa D. Mol Clin Oncol. 2022 Jan;16(1):21.

1. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA. J Clin Oncol. 2022 Jan 1;40(1):52-62.